The Use of Advanced pH, Time or Microbial-Dependent Oral Drug Delivery Technologies for Precise Release in the Colon

The colon has emerged as an optimal site for the oral delivery of drugs targeting inflammatory bowel diseases (IBDs) including Ulcerative Colitis (UC), Crohn’s disease (CD), Amebiosis or colonic cancer. The overall goal of colonic delivery is to achieve high drug concentrations that optimize localized absorption by reducing intestinal metabolic activity for acid and enzymatically labile products including proteins and peptides. While colon delivery has been an area of market focus for many decades, new approaches have recently been developed that combine pH, time or microbial-dependent systems into single or dual-coating layers for use with various oral solid dosage forms.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.